Lilly ICOS LLC to Release Financial Results for 2006
January 04, 2007
BOTHELL, Wash. & INDIANAPOLIS--(BUSINESS
WIRE)--Jan 4, 2007 - Lilly ICOS LLC (Lilly ICOS)
will announce its fourth quarter and 2006 full
year financial results after the U.S. markets
close on January 18, 2007.
Lilly, a leading innovation-driven corporation,
is developing a growing portfolio of first-in-class
and best-in-class pharmaceutical products by
applying the latest research from its own worldwide
laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis,
Ind., Lilly provides answers - through medicines
and information - for some of the world's most
urgent medical needs. Additional information
about Lilly is available at www.lilly.com. F-LLY
ICOS Corporation, a biotechnology company
headquartered in Bothell, Washington, is dedicated
to bringing innovative therapeutics to patients.
Through Lilly ICOS LLC, ICOS is marketing its
first product, Cialis(R)
(tadalafil) (1), for the treatment of erectile
dysfunction. ICOS is working to develop treatments
for serious unmet medical needs such as benign
prostatic hyperplasia, pulmonary arterial hypertension,
cancer, psoriasis and inflammatory diseases.
Except for historical information contained
herein, this press release contains forward-looking
statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on current
expectations, estimates and projections about
the industry, management beliefs and certain
assumptions made by the managements of ICOS
and Lilly. Investors are cautioned that matters
subject to forward-looking statements involve
risks and uncertainties, including economic,
competitive, governmental, technological, legal
and other factors discussed in the two companies'
respective filings with the Securities and Exchange
Commission, which may affect the business and
prospects of the two companies and Lilly
ICOS. Results and the timing and outcome
of events may differ materially from those expressed
or implied by the forward-looking statements
in this press release. More specifically, there
can be no assurance that Cialis will achieve
sustained commercial success or that competing
products will not pre-empt market opportunities
that might exist for the product.
The forward-looking statements contained in
this press release represent ICOS' and Lilly's
judgments as of the date of this release. Neither
ICOS nor Lilly undertake any obligation to update
any forward-looking statements.
Source:
http://www.pharmalive.com/News/index.cfm
|
|
